ABSTRACT. Grandaxin is effective in the treatment of the withdrawal of patients with chronic alcohol dependence, with the following specifications: as monotherapy, in uncomplicated alcohol withdrawal; with anticonvulsant-thymoregulatory and neuroleptic medication, in the withdrawal with delirium or other complications (e.g. convulsions), such drug combinations being very well tolerated by the patients in my diagnostic group, while shortening the duration of the withdrawal. It is also effective in neurotic disorders in which the clinical picture is governed by psychic or somatic manifestations of anxiety, in such cases showing its effectiveness by providing an early relief of symptoms. Mention should be made that the most common side effects (restlessness, insomnia, irritability), occurring at a dosage of 150-200 mg/day, were generally of low intensity and transient. In short, Grandaxin showed a very good degree of tolerability in all of the patients included in the study, which increased their compliance with treatment, while recommending it for long-term therapy.

Keywords: Grandaxin; alcohol withdrawal; neurotic disorders; benzodiazepine; anxiety; alcohol crave